ArticleClinical and experimental vaccine research2026
Survival after primary and booster COVID-19 vaccination in patients with COPD.
Article in Clinical and experimental vaccine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research trends in COPD-associated invasive pulmonary aspergillosis over the past two decades: a bibliometric and topic modelling analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the primary vaccination status against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the administration of variant-modified vaccine boosters and the 1-year survival due to coronavirus disease 2019 (COVID-19) in individuals over 65 years old diagnosed with chronic obstructive pulmonary disease (COPD). Materials and Methods: This cross-sectional study was conducted between July 2021 and February 2023. Among 108 COPD patients registered with the home healthcare unit, 97 were included after informed consent. Demographic and clinical characteristics (age, sex, vaccine type, dose count, smoking, diabetes, hypertension) were evaluated for their impact on mortality and survival. The Log-rank test assessed associations with one-year mortality, and Cox regression evaluated independent effects. Results: Among participants, 64% were aged 65-75 and 52% were male. Of these, 41% completed only the primary vaccination series (2 doses) and 29% received a booster dose. By one-year follow-up, 38% (n=37) had died due to COVID-19. Vaccination status (p=0.018), number of doses (p=0.017), and diabetes (p=0.001) were significantly associated with mortality. Cox analysis indicated diabetes (Exp[β]=3.125) and incomplete vaccination (Exp[β]=0.456) significantly decreased survival (p<0.05). Conclusion: Completing at least the primary vaccination series was associated with improved survival, while incomplete primary vaccination and comorbid diabetes had negative effects on outcomes. Booster dose uptake was lower than completion of the primary series. Routine SARS-CoV-2 vaccination remains essential for protecting vulnerable populations, especially amid the ongoing emergence of new variants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.